Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Change in Account Payables: 2022-2025

Historic Change in Account Payables for Taysha Gene Therapies (TSHA) over the last 4 years, with Sep 2025 value amounting to -$1.9 million.

  • Taysha Gene Therapies' Change in Account Payables rose 48.48% to -$1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $469,000, marking a year-over-year increase of 117.72%. This contributed to the annual value of -$2.9 million for FY2024, which is 27.23% down from last year.
  • According to the latest figures from Q3 2025, Taysha Gene Therapies' Change in Account Payables is -$1.9 million, which was down 164.98% from $3.0 million recorded in Q2 2025.
  • In the past 5 years, Taysha Gene Therapies' Change in Account Payables registered a high of $4.0 million during Q1 2024, and its lowest value of -$9.4 million during Q3 2022.
  • Over the past 3 years, Taysha Gene Therapies' median Change in Account Payables value was -$1.2 million (recorded in 2023), while the average stood at -$294,727.
  • Data for Taysha Gene Therapies' Change in Account Payables shows a peak YoY increase of 1,008.64% (in 2024) and a maximum YoY decrease of 191.55% (in 2024) over the last 5 years.
  • Quarterly analysis of 4 years shows Taysha Gene Therapies' Change in Account Payables stood at -$4.6 million in 2022, then spiked by 73.19% to -$1.2 million in 2023, then decreased by 22.28% to -$1.5 million in 2024, then skyrocketed by 48.48% to -$1.9 million in 2025.
  • Its Change in Account Payables stands at -$1.9 million for Q3 2025, versus $3.0 million for Q2 2025 and $923,000 for Q1 2025.